5 Top Weekly NASDAQ Biotech Stocks: vTv Increases 163 Percent
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
Your trusted source for investing success
Your trusted source for investing success
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
The Investing News Network rounds up some of the biggest company and market news in the cannabis market for the past trading week.
With Q2 2018 now in full swing, the Investing News Network is taking a look back at the biggest medical device trends in Q1 and what to look for now.
The cell-therapy company’s share price increased by over 90 percent after the milestone announcement was released on Thursday.
Hemostemix (TSXV:HEM), a clinical-stage, autologous cell-therapy company, is pleased to announce that the United States Food and Drug Administration has raised no objections to the Company’s Investigational New Drug application. This allows the Company to expand its Phase II clinical trial for critical limb ischemia to enroll patients at clinical sites
Adamas Pharmaceuticals (Nasdaq:ADMS) today announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based
Flexion Therapeutics (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone acetonide extended-release injectable suspension) have been published in the print and online edition of the Journal of Bone and Joint Surgery (Vol 100 (8) pp 666 – 677). ZILRETTA was approved by
Sientra (NASDAQ:SIEN) a medical aesthetics company, today announced U.S. Food and Drug Administration (FDA) approval of the Company’s PMA supplement allowing commercialization of its OPUS-branded breast implant products manufactured by Vesta, a Lubrizol LifeSciences company, at Vesta’s Wisconsin-based manufacturing facility.
As quoted in the press release:
Jeffrey M. Nugent, Chairman and Chief
By Pia Rivera
Kalytera Therapeutics, Inc. (TSXV:KALY. OTCQB:KALTF) announced that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol (“CBD”) for the treatment of severe and refractory graft versus host disease.
Medigus and HC Marbella International Hospital announced the first successful MUSE procedure for GERD treatment on a single patient in Spain.
Solid Biosciences (NASDAQ:SLDB) announced that the Company has received a letter from the U.S. Food and Drug Administration (FDA) relating to the previously-announced full clinical hold on IGNITE DMD, the Company’s Phase I/II clinical trial for its investigational gene therapy, SGT-001, for the treatment of Duchenne muscular dystrophy (DMD). The
Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma who have received
Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Cream USP, 0.05%. This is Teligent’s fourth approval for 2018, and its twenty-third approval from its
Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita® (burosumab-twza) for the
Shire has received another FDA approval with the second approval for Vonvendi, a treatment for perioperative bleeding management in adults with VWD.
Biomerica (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the period ended February 28, 2017. Sales for the three months ending February 28, 2018 were $1,375,666 compared to $1,499,930 for the period ended February 28, 2017.
As quoted in the
Shire (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease
Lexaria Bioscience Corp. (CSE:LXX,OTCQB:LXRP) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce positive topline results upon completion of its first ingestible nicotine in vivo (animal) absorption study.
Innovation Pharmaceuticals (OTCQB:IPIX) a clinical stage biopharmaceutical company, is pleased to report additional information from the Company’s successfully completed Phase 2 clinical trial of Brilacidin-OM (see NCT02324335) for the indication of decreasing the incidence of Severe Oral Mucositis (SOM) (WHO Grade ≥3) in Head and Neck Cancer (HNC) patients receiving
Cancer Genetics (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it has received special 510(k) clearance from the U. S. Food and Drug Administration (FDA) for its Tissue of Origin test following modifications made to test reagents and software.
As quoted in
